Neogenomics (NEO) EBT (2010 - 2026)

Neogenomics (NEO) has 17 years of EBT data on file, last reported at $1.8 million in Q2 2026.

• Quarterly EBT rose 103.99% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$54.5 million (up 48.27% YoY) and the FY2025 annual result came in at -$110.3 million, down 36.68% from the prior year.
• EBT advanced to $1.8 million in Q2 2026, from -$17.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.8 million in Q2 2026 to a low of -$53.2 million in Q1 2022.
• A 5-year average of -$25.7 million and a median of -$25.6 million in 2022 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT plunged 155.88% — and 2026, when it surged 103.99%.
• Tracing NEO's EBT over 5 years: stood at -$25.5 million in 2022, then soared by 40.11% to -$15.3 million in 2023, then fell by 5.51% to -$16.1 million in 2024, then climbed by 23.08% to -$12.4 million in 2025, then jumped by 114.72% to $1.8 million in 2026.
• The last three EBT figures came in at $1.8 million (Q2 2026), -$17.6 million (Q1 2026), and -$12.4 million (Q4 2025), per Business Quant data.